

Teresa Bernal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3515101/publications.pdf>

Version: 2024-02-01

124
papers

4,804
citations

201385

27
h-index

98622

67
g-index

134
all docs

134
docs citations

134
times ranked

6484
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	3.3	23
2	Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy [*]. <i>Leukemia and Lymphoma</i> , 2022, 63, 928-938.	0.6	9
3	Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving firstâ€line systemic treatment or best supportive care: A multicenter international study. <i>European Journal of Haematology</i> , 2022, 109, 58-68.	1.1	5
4	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.4	3
5	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. <i>Cancers</i> , 2022, 14, 2342.	1.7	4
6	Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 2817.	1.7	0
7	Evolving treatment patterns and outcomes in older patients (â‰¥60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	3.3	12
8	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology</i> , 2021, 8, e135-e148.	2.2	32
9	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	3.3	31
10	Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 311.e1-311.e10.	0.6	4
11	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	0.6	21
12	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. <i>Annals of Hematology</i> , 2021, 100, 1995-2004.	0.8	9
13	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021, 106, 3079-3089.	1.7	15
14	Expression of CD47 antigen in Reedâ€™Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 782-785.	1.2	9
15	Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. <i>Haematologica</i> , 2020, 105, 1559-1566.	1.7	32
16	Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. <i>Leukemia Research</i> , 2020, 92, 106352.	0.4	0
17	Strategy for identification of a potential inherited leukemia predisposition in a 299 patientâ€™s cohort with tumor-only sequencing data. <i>Leukemia Research</i> , 2020, 95, 106386.	0.4	3
18	A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories. <i>Blood</i> , 2020, 136, 9-10.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial. <i>Blood</i> , 2020, 136, 28-29.	0.6	8
20	Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. <i>Blood</i> , 2020, 136, 25-27.	0.6	3
21	Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 13-15.	0.6	1
22	Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
23	Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of <i>ASXL1</i> Chromosomal Deletion and Genetic Mutations. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
24	Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
25	Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
26	Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. <i>Nucleic Acids Research</i> , 2019, 47, 5016-5037.	6.5	23
27	The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1985.	1.0	6
28	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	0.6	9
29	Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group. <i>Blood</i> , 2019, 134, 844-844.	0.6	3
30	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. <i>Blood</i> , 2019, 134, 648-648.	0.6	1
31	Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry. <i>Blood</i> , 2019, 134, 1321-1321.	0.6	0
32	Strategy for Identification of an Inherited Leukemia Predisposition in a 299 Patients Cohort with Tumor-Only Sequencing Data. <i>Blood</i> , 2019, 134, 1415-1415.	0.6	7
33	Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes. <i>Blood</i> , 2019, 134, 4226-4226.	0.6	0
34	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2018, 68, 79-84.	0.4	9
35	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 146-154.	0.6	17
36	Long-term outcome of older patients with newly diagnosed <i>de novo</i> acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. <i>Leukemia</i> , 2018, 32, 21-29.	3.3	24

#	ARTICLE	IF	CITATIONS
37	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. <i>Leukemia</i> , 2018, 32, 2546-2557.	3.3	101
38	The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <i>Leukemia Research</i> , 2018, 70, 34-36.	0.4	15
39	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	0.6	44
40	Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) " Preliminary Blinded Analysis of the European Sintra-REV Trial. <i>Blood</i> , 2018, 132, 468-468.	0.6	3
41	Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization. <i>Blood</i> , 2018, 132, 3048-3048.	0.6	0
42	Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction. <i>Blood</i> , 2018, 132, 4339-4339.	0.6	0
43	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Leukemia and Lymphoma</i> , 2017, 58, 145-152.	0.6	7
44	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. <i>Annals of Hematology</i> , 2017, 96, 1069-1075.	0.8	21
45	Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence. <i>Leukemia Research</i> , 2017, 55, S52.	0.4	0
46	What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools. <i>Leukemia Research</i> , 2017, 55, S150-S151.	0.4	0
47	The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment. <i>Annals of Hematology</i> , 2017, 96, 1833-1840.	0.8	16
48	Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Aggressive B Cell Lymphoma: A GELTAMO Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 53-59.	2.0	12
49	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. <i>BMC Cancer</i> , 2017, 17, 852.	1.1	57
50	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017, 35, 1591-1597.	0.8	79
51	A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7068-TPS7068.	0.8	6
52	Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. <i>Oncotarget</i> , 2017, 8, 31959-31976.	0.8	39
53	Impact of Initial Ventilatory Strategy in Hematological Patients With Acute Respiratory Failure: A Systematic Review and Meta-Analysis*. <i>Critical Care Medicine</i> , 2016, 44, 1406-1413.	0.4	28
54	Blood, Sweat, and teARDS*. <i>Critical Care Medicine</i> , 2016, 44, 1235-1236.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 33-38.	1.1	23
56	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. <i>Leukemia Research</i> , 2016, 41, 12-20.	0.4	41
57	Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply. <i>Leukemia</i> , 2016, 30, 740-741.	3.3	1
58	Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. <i>Nature Medicine</i> , 2016, 22, 91-96.	15.2	37
59	Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. <i>Leukemia and Lymphoma</i> , 2016, 57, 86-91.	0.6	14
60	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). <i>Blood</i> , 2016, 128, 1638-1638.	0.6	2
61	Comparison of Efficacy and Safety of Two Types of E.coli Asparaginase (Native or Pegylated) for Treatment of Adult Patients with High-Risk (HR), Philadelphia (Ph) Chromosome-Negative ALL Included in the Prospective MRD-Oriented Protocol ALL-HR-11 from the Spanish Pethema Group. <i>Blood</i> , 2016, 128, 180-180.	0.6	3
62	Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA. <i>Blood</i> , 2016, 128, 448-448.	0.6	3
63	Analysis of Transfusion Dependency Development and Disease Evolution in Patients with MDS with 5q- and without Transfusion Needs at Diagnosis. <i>Blood</i> , 2016, 128, 3180-3180.	0.6	1
64	Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalities (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group. <i>Blood</i> , 2016, 128, 1602-1602.	0.6	0
65	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> , 2015, 126, 291-299.	0.6	982
66	Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. <i>Leukemia</i> , 2015, 29, 1875-1881.	3.3	93
67	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015, 39, 52-57.	0.4	18
68	83 PERCENTAGE OF BLASTS IN CHRONIC MYELOMONOCYTIC LEUKEMIA TYPE-1 HAS NO IMPACT ON OVERALL SURVIVAL IN A SERIES OF PATIENTS FROM THE SPANISH REGISTRY OF MDS. <i>Leukemia Research</i> , 2015, 39, S40-S41.	0.4	0
69	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	0.6	9
70	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. <i>Blood</i> , 2015, 126, 2723-2723.	0.6	1
71	A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD. <i>Blood</i> , 2015, 126, 2896-2896.	0.6	6
72	How Are Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS) Treated? Impact on Clinical Evolution and Overall Survival: A Report from the Erasme Study. <i>Blood</i> , 2015, 126, 5239-5239.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Impact of Treatment on Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (MDS): A Report from the Erasme Study. <i>Blood</i> , 2015, 126, 5240-5240.	0.6	0
74	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, 505-510.	1.7	34
75	Results of treatment with azacitidine in patients aged \geq 75 years included in the Spanish Registry of Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1300-1303.	0.6	16
76	Robotic Retroperitoneal Paraaortic Lymphadenectomy at Donostia University Hospital. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 480-485.	0.3	6
77	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 551-556.	0.4	11
78	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Cancer</i> , 2014, 120, 3958-3964.	2.0	24
79	Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1595-1604.	0.8	227
80	Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients. <i>Leukemia Research</i> , 2014, 38, 1199-1206.	0.4	9
81	Myocardial Injury after Noncardiac Surgery. <i>Anesthesiology</i> , 2014, 120, 564-578.	1.3	740
82	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, e126-e126.	1.7	8
83	IMPACT of Therapeutic Strategy and Time to Therapy Initiation on Clinical Evolution in Higher-Risk Myelodysplastic Syndromes. a Report from Erasme Study. <i>Blood</i> , 2014, 124, 1908-1908.	0.6	2
84	IMPACT of Therapeutic Strategy and Time to Therapy Initiation on Clinical Evolution of Patients with NEWLY Diagnosed Chronic Myelomonocytic Leukemia. a Report from Erasme Study. <i>Blood</i> , 2014, 124, 5607-5607.	0.6	0
85	Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors. <i>Cancer Research</i> , 2013, 73, 395-405.	0.4	69
86	Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia. <i>Experimental Hematology</i> , 2013, 41, 172-179.	0.2	9
87	Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. <i>Cancer</i> , 2013, 119, 1660-1668.	2.0	63
88	Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. <i>Critical Care</i> , 2013, 17, R302.	2.5	16
89	Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis. <i>Blood</i> , 2013, 122, 1542-1542.	0.6	0
90	Applicability Of The Predictive Model Of Response To Erythropoetic Stimulating Agents (ESA) From Myelodysplastic Syndromes (MDS) and Analysis Of Response and Overall Survival (OS) In a Series Of 99 Patients (Pts) With Chronic Myelomonocytic Leukemia (CMML) From The Spanish Registry Of MDS and The Düsseldorf-MDS Registry, Germany. <i>Blood</i> , 2013, 122, 2813-2813.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score. <i>Blood</i> , 2013, 122, 2754-2754.	0.6	0
92	Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era: comparison of two prospective parallel protocols. <i>British Journal of Haematology</i> , 2012, 159, 485-488.	1.2	15
93	Ventilatory support in critically ill hematology patients with respiratory failure. <i>Critical Care</i> , 2012, 16, R133.	2.5	87
94	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 287-292.	0.4	22
95	Autologous Stem Cell Transplantation with Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial. <i>Blood</i> , 2012, 120, 1978-1978.	0.6	2
96	Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols. <i>Blood</i> , 2012, 120, 4785-4785.	0.6	0
97	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.	1.7	226
98	In vitro study of the magnetic resonance imaging artifacts of six supraglottic airway devices. <i>European Journal of Anaesthesiology</i> , 2010, 27, 244-245.	0.7	2
99	Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. <i>Blood</i> , 2010, 116, 3157-3162.	0.6	49
100	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2010, 89, 453-458.	0.8	40
101	Intubation of obstructive sleep apnea patient: Comparative study between conventional laryngoscopy and Airtraq®. <i>European Journal of Anaesthesiology</i> , 2010, 27, 263.	0.7	0
102	Long FLT3 internal tandem duplications and reduced PML-RAR α expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. <i>Haematologica</i> , 2010, 95, 745-751.	1.7	47
103	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. <i>Haematologica</i> , 2010, 95, 589-596.	1.7	240
104	Clinical Experience with Azacitidine In Secondary Myelodysplastic Syndrome In Spain. <i>Blood</i> , 2010, 116, 1852-1852.	0.6	3
105	Effectiveness of Various Dosage Regimens of Azacitidine In Patients with Myelodysplastic Syndromes: Safety and Efficacy Final Data From the Spanish Azacitidine Compassionate Use Registry. <i>Blood</i> , 2010, 116, 1853-1853.	0.6	1
106	Azacitidine In Compassionate Use: Response to Therapy, Survival, and Prognostic Factors In 200 Patients Diagnosed with MDS or AML. <i>Blood</i> , 2010, 116, 2933-2933.	0.6	0
107	P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2009, 33, S74-S75.	0.4	0
108	P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2009, 33, S75-S76.	0.4	5

#	ARTICLE	IF	CITATIONS
109	P136 Allogenic stem cell transplant in MDS: results of the Spanish registry. <i>Leukemia Research</i> , 2009, 33, S138-S139.	0.4	0
110	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. <i>Leukemia Research</i> , 2009, 33, 1706-1709.	0.4	49
111	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2009, 114, 148-152.	0.6	78
112	Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.. <i>Blood</i> , 2009, 114, 322-322.	0.6	5
113	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 577-584.	0.8	213
114	Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. <i>Blood</i> , 2008, 112, 2539-2545.	0.6	268
115	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. <i>Haematologica</i> , 2008, 93, 1797-1805.	1.7	41
116	370: Fludarabine-busulphan reduced intensity conditioning (RIC) identical sibling allogeneic stem cell transplantation (allo-SCT) in high risk acute myeloid leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 134-135.	2.0	1
117	R-ESHAP as Salvage Therapy for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Spanish GEL-TAMO Multicenter Study.. <i>Blood</i> , 2007, 110, 3438-3438.	0.6	17
118	Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 172-183.	2.0	135
119	Fludarabine and Busuphan (Flu-Bu) as Reduced Intensity-Conditioning (RIC) Regimen in HLA-Identical Sibling Allogeneic Hematopoietic Stem Transplantation (Allo-SCT) for Myeloid Malignancies. Results of a Prospective Multicenter Study.. <i>Blood</i> , 2006, 108, 5363-5363.	0.6	0
120	Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34 ⁺ bone marrow cell compartments from patients with myelodysplastic syndromes. <i>Leukemia</i> , 2004, 18, 1311-1313.	3.3	7
121	Prognostic Factors and Long-Term Outcome for Patients with Hodgkin TM s Lymphoma Who Relapse after an Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1649-1649.	0.6	5
122	Secondary Malignancies after Autologous Stem Cell Transplantation for Hodgkin TM s Lymphoma: Incidence and Analysis of Risk Factors.. <i>Blood</i> , 2004, 104, 60-60.	0.6	0
123	Trisomy 10 in acute myeloid leukemia: Report of a new case. <i>Cancer Genetics and Cytogenetics</i> , 1998, 100, 84-87.	1.0	10
124	Altered Cell-Mediated Immunity in Asymptomatic Colombian Natives With Positive or Indeterminate Serology for HTLV-I. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 121-123.	0.3	1